Limitations of CAR-T are well known.
Having the platform which safely and effectively does the work and being able to pop on all the different targeters to create different drugs feels like what BP would be far more interested in.
- Forums
- ASX - By Stock
- IMU
- Ann: First Australian Patient Dosed in Phase 1b azer-cel Trial
IMU
imugene limited
Add to My Watchlist
7.14%
!
1.3¢

Ann: First Australian Patient Dosed in Phase 1b azer-cel Trial, page-217
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M |
Open | High | Low | Value | Volume |
1.4¢ | 1.4¢ | 1.3¢ | $143.5K | 10.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
78 | 19078796 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 6091128 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
78 | 19078796 | 0.013 |
66 | 14045547 | 0.012 |
19 | 4930116 | 0.011 |
37 | 9292022 | 0.010 |
5 | 961155 | 0.009 |
Price($) | Vol. | No. |
---|---|---|
0.014 | 6062487 | 14 |
0.015 | 10817566 | 46 |
0.016 | 10136745 | 37 |
0.017 | 8708633 | 19 |
0.018 | 5121090 | 23 |
Last trade - 12.10pm 18/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online